Skip to main content
VBIO logo

VBIO · Valion Bio, Inc. · Webcasts, Transcripts & Audio

Track VBIO — free
$1.12 -0.07 (-5.88%) At close · Oct 21
Market Cap
$1.05M
Shares
887,590
Volume · Oct 21 202.17K Avg daily vol (37 sessions) 2.33M

Valion Bio, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Valion Bio, Inc. (VBIO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q1
2026-05-14
Valion Bio, Inc. (VBIO) Q1 2026 Earnings Call Transcript
Positive tone Velocity Bioworks (CDMO / biomanufacturing) Government engagement and federal funding for Entolamod Corporate rebranding and governance
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Valion Bio, Inc. (VBIO) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Valion Bio, Inc. (VBIO) Q3 2025 Earnings Call Transcript
Confident tone Entolimod for acute radiation syndrome (ARS) Strategic transformation to biopharmaceuticals VNS (vagus nerve stimulation) program
Revenue
$146,000
▲ 15.9% YoY
Gross margin
-99.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Valion Bio, Inc. (VBIO) Q2 2025 Earnings Call Transcript
Confident tone Entolimod for Acute Radiation Syndrome (ARS) Government/defense stockpile opportunity Consumer Health Tech (ClearUP) wind-down
Revenue
$86,000
▼ 38.6% YoY
Diluted EPS
$-54.75
Gross margin
62.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Valion Bio, Inc. (VBIO) Q1 2025 Earnings Call Transcript
Confident tone Entolimod licensing and TLR5 program Government / agency relationships and funding Non-invasive vagus nerve stimulation (VNS) program
Revenue
$70,000
▼ 79% YoY
Diluted EPS
$-63.00
Gross margin
71.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Valion Bio, Inc. (VBIO) Q4 2024 Earnings Call
Revenue
$180,000*
▼ 49.6% YoY
Gross margin
-132.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Valion Bio, Inc. (VBIO) Q3 2024 Earnings Call Transcript
Positive tone Vagus nerve stimulation (VNS) program ClearUP product line turnaround Capital raising strategy
Revenue
$126,000
▼ 55.3% YoY
Diluted EPS
$-97.75
Gross margin
34.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Valion Bio, Inc. (VBIO) Q2 2024 Earnings Call Transcript
Positive tone VNS program / clinical results ClearUP product line Intellectual property and patents
Revenue
$140,000
▼ 13% YoY
Diluted EPS
$-134.25
Gross margin
21.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Valion Bio, Inc. (VBIO) Q4 2023 Earnings Call Transcript
Positive tone Vagus nerve stimulation (VNS) research Gross profit and margin improvement Distribution partnerships
Revenue
$357,000*
▼ 12.3% YoY
Gross margin
1.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Valion Bio, Inc. (VBIO) Q3 2023 Earnings Call Transcript
Revenue
$282,000
▼ 40.9% YoY
Diluted EPS
$-629.00
Gross margin
38.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Valion Bio, Inc. (VBIO) Q2 2023 Earnings Call Transcript
Revenue
$161,000
▼ 69.5% YoY
Diluted EPS
$-3043.00
Gross margin
37.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Valion Bio, Inc. (VBIO) Q1 2023 Earnings Call
Revenue
$376,000
▼ 12.1% YoY
Diluted EPS
$-4471.00
Gross margin
30.1%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-31
Valion Bio, Inc. (VBIO) Q4 2022 Earnings Call
Revenue
$407,000*
▲ 4.6% YoY
Gross margin
10.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Valion Bio, Inc. (VBIO) Q3 2022 Earnings Call
Revenue
$477,000
▲ 72.2% YoY
Diluted EPS
$-11475.00
Gross margin
13.2%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Valion Bio, Inc. (VBIO) Q2 2022 Earnings Call
Revenue
$528,000
▲ 97% YoY
Diluted EPS
$-13600.00
Gross margin
23.7%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Valion Bio, Inc. (VBIO) Q1 2022 Earnings Call
Revenue
$428,000
▲ 32.5% YoY
Diluted EPS
$-9775.00
Gross margin
16.4%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 webcasts
Key facts CIK 1787740 CUSIP 918942202 Visit website Investor relations